Table 1 Subject characteristics in the exploratory and validation sample sets
From: Methylation analysis of plasma DNA informs etiologies of Epstein-Barr virus-associated diseases
| Â | Non-NPC subjects with transiently positive plasma EBV DNA in the exploratory set | Non-NPC subjects with persistently positive plasma EBV DNA in the exploratory set | NPC patients from the screening cohort in the exploratory set | Non-NPC subjects with transiently positive plasma EBV DNA in the validation set | Non-NPC subjects with persistently positive plasma EBV DNA in the validation set | NPC patients from the screening cohort in the validation set | NPC patients from an external cohort in the validation set |
|---|---|---|---|---|---|---|---|
Number | 20 | 20 | 10 | 90 | 30 | 23 | 14 |
Sex | |||||||
 M | 20 | 20 | 10 | 90 | 30 | 23 | 13 |
 F | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
 Median age, year (IQR) | 53.5 (46–57) | 48 (43–58) | 52.5 (49–55) | 54 (49–58) | 54 (49–59) | 52 (44.5–55) | 57 (45.5–62) |
Tumour stage | |||||||
 I | NA | NA | 5 | NA | NA | 10 | 2 |
 II | NA | NA | 1 | NA | NA | 7 | 0 |
 III | NA | NA | 4 | NA | NA | 4 | 5 |
 IV | NA | NA | 0 | NA | NA | 2 | 7 |
